Abstract
Introduction
Moderate successes and "business as usual" characterize the performance of the
pharmaceutical industry in 2007. In this year-end retrospective report, we
contemplate the importance of key events and achievements in the industry. We
asked industry-leading experts to identify particularly noteworthy events in
2007 and lessons that can be learned for 2008. Six themes emerged; our experts
discuss their implications for the industry. Furthermore, we offer a Spectrum
Scorecard that assesses industry performance in a variety of critical areas.
Get the Answers You Need to Shape Your Strategy
- The pharmaceutical industry may never be to return to its glory days, but
it can exert control over its future through the strategies and changes that
it is willing to adopt today. What strategic options are essential to
achieve success in today' s evolving markets? What are the future implications
of these changes for pharmaceutical companies?
- Pharmaceutical companies must ensure they are "fi t for purpose" in
today' s business environment. What strategies can pharmaceutical management
pursue to capture and harness the essence of a resultsoriented business and
make their companies truly fi t for purpose? How can they uncover previously
unrealizable profi ts and growth and also differentiate themselves so that
they can grasp valuable competitive advantage?
Scope
- 2007 in review: a retrospective on news and key themes from the
year.
- Seeking a new vision for the pharmaceutical industry: looking for
the Holy Grail of opportunity.
- Negative industry impacts: from generics erosion, biogenerics,
declining productivity, and drug safety concerns combined with the increased
importance of specialty pharma and biotech.
- New strategies needed for future success: rethinking the
blockbuster strategy, a holistic approach to management style, fi t with
strategy, choosing strategies and opportunities wisely.
- Jumping on technology opportunities: identifying key technologies
and turning innovation into new products and services.
- New value propositions: value-for-money.
- Growing infl uence of U.S. states: legislative bills, litigation by
state attorneys general, lessons learned.
- 2007 industry report card: how successful was Big Pharma in
capitalizing on the many opportunities available in 2007?
View Cart
